Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WG109
- Development stage
- Unknown
- Lead developer
- Wingor Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
WG109 is an investigational cell therapy consisting of human umbilical cord mesenchymal stem cells (hUC-MSCs), developed by Wingor Biotechnology. It is primarily designed to treat ischemic stroke, specifically subacute ischemic stroke, and is also being evaluated for acute respiratory distress syndrome (ARDS). Mesenchymal stem cells exert therapeutic effects through immunomodulation, anti-inflammatory activity, and the secretion of trophic factors that promote neurogenesis, angiogenesis, and tissue repair. WG109 is currently in Phase II clinical development in China for subacute ischemic stroke.
- Other names
- hUC-MSCshuman umbilical cord mesenchymal stem cells人脐带间充质干细胞
Beyond the preview
Go deeper on WG109.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WG109.